Organigram Reports Steep Q2 Profitability Decline, $5.8M Impairment, and Revised FCF Guidance

summarizeSummary

Organigram Global reported a sharp drop in Q2 profitability and a $5.8 million impairment from U.S. hemp regulations, alongside a downgrade in free cash flow guidance, despite raising full-year revenue targets due to an acquisition.

check_boxKey Events

• Q2 Profitability Plummets

  Net revenue decreased 9% to $59.8 million, and Adjusted EBITDA fell 82% to $0.9 million year-over-year, resulting in a net loss of $0.9 million.

• Significant Impairment Charge

  The company recognized a $5.8 million impairment related to its U.S. hemp-derived products business due to new regulatory restrictions, which will effectively eliminate these products by November 2026.

• Revised Fiscal 2026 Outlook

  While full-year net revenue guidance was increased to exceed $350 million (incorporating the Sanity Group acquisition), free cash flow guidance was downgraded from positive to approximately break-even.

• U.S. Cannabis Market Developments

  The company is evaluating options for entering the U.S. medical cannabis market following the federal rescheduling of cannabis to Schedule III for approved products.

auto_awesomeAnalysis

Organigram Global reported a significant decline in Q2 Fiscal 2026 profitability, with net revenue down 9% and Adjusted EBITDA plummeting 82% year-over-year, resulting in a net loss. The company also recognized a $5.8 million impairment charge related to its U.S. hemp-derived products business due to new regulatory restrictions. While full-year revenue guidance was raised due to the recent Sanity Group acquisition, free cash flow guidance was downgraded from positive to approximately break-even. The company is exploring options for the U.S. medical cannabis market following federal rescheduling.